Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma

OBJECTIVE: The purposes of this study were to observe the effects of different treatment strategies, including third-line pemetrexed alone versus its combination with bevacizumab, in patients with advanced epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma, and to analyze...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Chin J Cancer Res
Главные авторы: Zhou, Cheng-Zhi, Qin, Yin-Yin, Xie, Zhan-Hong, Zhang, Jie-Xia, Ou-Yang, Ming, Li, Shi-Yue, Chen, Rong-Chang
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2014
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4279200/
https://ncbi.nlm.nih.gov/pubmed/25561769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2014.12.19
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы